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Reliable detection of JAK2-V617F is critical for accurate diagnosis of myeloproliferative neoplasms (MPNs); in addition, sensitive
mutation-speciﬁc assays can be applied to monitor disease response. However, there has been no consistent approach to
JAK2-V617F detection, with assays varying markedly in performance, affecting clinical utility. Therefore, we established a network of
12 laboratories from seven countries to systematically evaluate nine different DNA-based quantitative PCR (qPCR) assays, including
those in widespread clinical use. Seven quality control rounds involving over 21 500 qPCR reactions were undertaken using
centrally distributed cell line dilutions and plasmid controls. The two best-performing assays were tested on normal blood samples
(n¼ 100) to evaluate assay speciﬁcity, followed by analysis of serial samples from 28 patients transplanted for JAK2-V617F-positive
disease. The most sensitive assay, which performed consistently across a range of qPCR platforms, predicted outcome following
transplant, with the mutant allele detected a median of 22 weeks (range 6–85 weeks) before relapse. Four of seven patients
achieved molecular remission following donor lymphocyte infusion, indicative of a graft vs MPN effect. This study has established a
robust, reliable assay for sensitive JAK2-V617F detection, suitable for assessing response in clinical trials, predicting outcome and
guiding management of patients undergoing allogeneic transplant.
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INTRODUCTION
The discovery of the JAK2-V617F mutation in 2005 transformed
the diagnostic work-up of myeloproliferative neoplasms (MPNs),
which occurs inB98% of polycythemia vera (PV) cases andB50%
with primary myeloﬁbrosis (PMF) and essential thrombo-
cythemia (ET).1–6 It has become clear that the level of the mutant
allele detectable in bona ﬁde MPN cases can be as low as 1–3%,6–9
which has implications for the diagnostic methods used, as such a
level would not be detectable by conventional Sanger sequencing
or pyrosequencing, and could potentially be missed by allele-
speciﬁc/ampliﬁcation refractory mutation system PCR.10–12
Quantitative PCR (qPCR) can afford much greater speciﬁcity and
thereby sensitivity; a considerable number of assays have been
developed,10 which have been applied to quantify the relative
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level of the mutant allele, to gain further insights into disease
biology and distinguish subsets of patients with differing clinical
features and outcome. Mutant allele burden has been correlated
with the risk of thrombotic events in ET, severity of the disease
phenotype in PV and survival in PMF.13–20 JAK2-V617F has also
been quantiﬁed to assess disease response, with signiﬁcant
reductions in allele burden reported in PV patients following
interferon a-2b and pegylated interferon a-2a treatment.21–25
Moreover, serial DNA-based qPCR assays have been used
after allogeneic transplantation for PMF to predict outcome,26–30
with patients with an allele burden 41% on day 28 post-
transplant30 or failing to achieve molecular remission in the
peripheral blood (PB) by 6 months post-allograft being at a
signiﬁcant risk of relapse,29 which can potentially be prevented by
donor lymphocyte infusion (DLI).26,31–32
In addition to helping guide management in the transplant
setting, quantiﬁcation of JAK2-V617F is being considered as an
end point in a number of trials with novel agents, including JAK
inhibitors. Studies to date indicate that JAK inhibitors have a
relatively limited impact on JAK2-V617F allele burden,33–36
whereas, a recent study with the novel telomerase inhibitor
imetelstat, showed a substantial decrease in JAK2-V617F allele
burden.37 It is critically important that assays used at baseline to
potentially distinguish biological subsets of disease and
subsequently to track treatment response are robust, mutant-
speciﬁc and afford a suitable level of speciﬁcity. On the basis of
experience of molecular monitoring in other hematological
malignancies within the European LeukemiaNet (ELN), we
reasoned that the plethora of qPCR assays routinely used to
detect JAK2-V617F could vary markedly in their performance,
potentially impacting on their clinical utility. Therefore, we
established a joint initiative between working groups within the
ELN and MPN&MPNr-EuroNet to evaluate in systematic fashion a
large number of widely used published and ‘in-house’ JAK2-V617F
qPCR assays, leading to the identiﬁcation of an assay that, beyond
being robust enough for routine diagnostic purposes, also showed
the best performance proﬁle when used for predicting outcome
following an allogeneic transplant.
MATERIALS AND METHODS
Detection of JAK2-V617F mutant allele by quantitative PCR (qPCR)
assays
Genomic DNA was extracted from cell lines and human PB samples using
standard methods. DNA was ampliﬁed (25 ng template per well) using
different qPCR assays designed to detect wild-type JAK2 (JAK2-WT) and the
JAK2 1849G4T mutation encoding JAK2-V617F (designated JAK2-V617F
assay), in parallel with independent control gene assays for Cyclophilin A38
and Albumin (ALB),39 providing a control for any variation in the amount of
template DNA between reaction wells, as well as between successive
quality control (QC) rounds (see Supplementary Table 1 for primer and
probe sequences). The evaluation encompassed a number of unpublished
‘in-house’ assays (n¼ 3), together with a large range of published assays
(n¼ 6).26,40–44 The latter included assays that have been widely applied in
clinical practice, that is, those forming the basis of the MutaQuant kit
(Qiagen, Marseille, France),41 or reported to predict outcome and used
to guide management following allogeneic transplantation.26,29,31–32
For published assays, reported reaction conditions were used; whereas
for ‘in-house’ assays, the reaction conditions used were provided by the
respective source laboratories. Assays were run in duplicate in the QC
rounds and in triplicate wells for the analysis of control PB and primary
patient samples with appropriate water controls.
Selection of the best-performing JAK2-V617F qPCR assay
A network of 12 laboratories with a particular interest in molecular
diagnosis of myeloid neoplasms and development of real-time qPCR
assays for minimal residual disease (MRD) detection was established by
the ELN in conjunction with the MPN&MPNr-EuroNet consortium
(see www.leukemia-net.org/ and www.mpneuronet.eu/). The study
involved central distribution of test materials for seven QC rounds
comprising cell line DNA and plasmid standards (see Figure 1). qPCR
reagents were also centrally distributed together with reaction conditions
to be used for each respective assay, which was assigned a different code
number in each successive QC round. qPCRs were predominantly
performed on Applied Biosystems platforms (ABI7000/7300/7500/7900;
Applied Biosystems, Foster City, CA, USA), two laboratories used the
Lightcycler LC480 platform (Roche Applied Science, Penzberg, Germany)
and one used a Rotor-Gene 6000 instrument (Corbett Life Science (now
Qiagen), Sydney, Australia). Laboratories with established published or
in-house qPCR assays were encouraged to perform these in parallel with
the coded test assays on the distributed QC materials, to control for local
variations in test conditions. Raw data from each QC round were submitted
by participating laboratories for independent central analysis (Department
of Genetics, King’s College, London); conclusions were drawn concerning
the performance of the various assays before breaking the code to reveal
their identities.
The relative efﬁciency of JAK2-WT, JAK2-V617F, Cyclophilin and ALB
assays was determined using serial dilutions of respective plasmid
standards (gift from Ipsogen (now Qiagen Marseille), Marseille, France),
as described.45,46 To investigate the speciﬁcity of the JAK2-WT and
JAK2-V617F assays, genomic DNA extracted from undiluted HEL and K562
cells (which harbor only JAK2-V617F and wild-type JAK2, respectively) was
analyzed. The capacity afforded by the different JAK2-V617F assays to
Figure 1. Summary of QC rounds used to identify JAK2-V617F assays
with the best performance profile. Seven successive QC rounds,
designated QC1–7, were conducted involving the assessment of
plasmid standards and DNA derived from dilutions of cell lines
harboring JAK2-V617F (HEL or UKE-1) in cells with wild-type JAK2
(K562 or PB mononuclear cells), abbreviated: HEL/K562,
UKE-1/PBMNC, as indicated. Assays found to exhibit consistently
poorer performance in multiple test laboratories were not taken
forward to subsequent QC rounds—reasons for assay exclusion are
provided. Details of the JAK2-V617F assays (designated Assays 1–9)
and control gene assays (Albumin, Cyclophilin) are provided in
Supplementary Table 1.
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detect the mutant allele was established through the analysis of DNA
extracted from serial dilutions of JAK2-V617F mutant cells (HEL or UKE-1)
in K562 cells. The level of JAK2-V617F at each dilution within the 5–100%
range of the distributed cell line sample DNA was veriﬁed by
pyrosequencing. The detection limit of each JAK2-V617F assay was
designated as the lowest dilution of the mutant cell line giving rise to
ampliﬁcation signiﬁcantly above the background level (that is, normalized
JAK2-V617F DCtX1) observed in undiluted K562 cells and with a cycle
threshold (Ct) value p40. The speciﬁcity of the best-performing JAK2-
V617F assays was investigated further, analyzing a large cohort of control
PB samples (n¼ 100) taken from individuals with no history of MPN.
Overall, Assay 5 was found to have the best performance proﬁle and was
selected as the ELN/COST JAK2 assay: forward primer 50-CTTTCTTTGAAGCA
GCAAGTATGA-30 , reverse primer JAK2-WT 50-GTAGTTTTACTTACTCTCGTCTC
CACATAC-30 , reverse primer JAK2-V617F 50-GTAGTTTTACTTACTCTC
GTCTCCACATAA-30 , probe 6FAM-TGAGCAAGCTTTCTCACAAGCATTTGGTTT
TAMRA.
Evaluation of JAK2-V617F qPCR assays in patients undergoing
allogeneic transplantation
Stored PB DNA samples (n¼ 220) from a cohort of 28 patients undergoing
allogeneic transplantation for JAK2-V617F-associated myeloid neoplasms
(2 PV, 16 myeloﬁbrosis, 8 transformed MPN and 2 JAK2-V617F mutant
chronic myelomonocytic leukemia) were analyzed. Given their older age
(median 54 years, range 21–67 years), the majority received reduced
intensity conditioning regimens. A median of seven samples were available
per patient (range 3–14). All samples were considered evaluable on the
basis of ALB Ct value (median 26, range 21–30). JAK2-V617F was quantiﬁed
using the DCt method, as described.47 Samples were deﬁned as qPCR
positive for JAK2-V617F when the DCt value between the ALB and JAK2
mutant assays was below the background level of ampliﬁcation detected
in normal PB samples (see below) in at least two of three replicate wells
with Ct valuesp40 (threshold 0.1),that is, DCtJAK2-V617F-ALBo13.3 for Assay
5 ando11.7 for Assay 7. qPCR results were compared with chimerism data
provided by the laboratories serving the respective transplant centers.
Patient samples were provided following informed consent in accordance
with the Declaration of Helsinki and analyses were subject to institutional
ethical approval (Guy’s and St Thomas’ Local Research Ethics Committee
ref 06/Q0702/140).
RESULTS
QC rounds to identify JAK2-V617F qPCR assays with the best
performance proﬁle in the diagnostic (JAK2-V617F range:
0.5–100%) and MRD detection (JAK2-V617F o1%) ranges.
In order to obtain some information concerning possible
variability in JAK2-V617F quantiﬁcation between laboratories,
freeze-dried cells from a 1 in 30 dilution of HEL cells (which
harbor multiple copies of JAK2-V617F and lack the wild-type JAK2
allele) in K562 cells (WT JAK2) were provided to ﬁve ELN member
laboratories by the UK National External Quality Assessment
Service (UK NEQAS, Shefﬁeld, UK). The test sample was estimated
to comprise B10% JAK2-V617F; however, the recipient labo-
ratories who each used their own established JAK2-V617F qPCR
assay reported markedly differing levels of mutant allele
percentage, ranging from 23 to 80% (see Supplementary
Figure 1). This highlighted the limitations of categorization of
MPNs as having heterozygous or homozygous JAK2-V617F
mutations on the basis of conventional qPCR assays and
emphasized the need for greater standardization. The aim was
to identify qPCR assays with sufﬁcient speciﬁcity and sensitivity,
and comparable interlaboratory performance irrespective of qPCR
platform, that are robust enough to be used for routine diagnostic
purposes, as well as for tracking MRD after disease-modifying
therapies (for example, interferon, stem cell transplantation),
where a o1% detection limit is required. A series of seven QC
rounds (QC1–7) were conducted (see Figure 1), which between
them involved 12 laboratories (11 European, 1 US), spread
between 7 countries. This analysis included consideration of
a number of qPCR assays that have been widely reported to track
treatment response, including post-transplant surveillance. In QC1,
six assays were evaluated on DNA from the serial dilutions of HEL
in K562 cells; qPCRs that used differently labeled probes to detect
the mutant and wild-type alleles in the same reaction (that is,
Assays 1(ref. 40) and 3(ref. 42)) were found to be too insensitive to be
suitable for MRD detection and were not considered further.
In addition, Assay 4(ref. 26) which has been widely applied
for post-transplant surveillance, was observed to perform
inconsistently between laboratories, and as it afforded poorer
sensitivity compared with Assay 5 in head to head testing, it was
also eliminated at this stage.
Assays 2(ref. 41), 5(ref. 43) and 6(ref. 44) were reanalyzed in QC2 and
taken forward to QC3 which involved the evaluation of
an additional in-house JAK2-V617F assay (Assay 7, Elisabeth
Oppliger Leibundgut, University of Bern, unpublished), together
with established assays for independent-control genes, that is,
Cyclophilin A38 and ALB,39 which were tested on cell line dilutions,
as well as plasmid standards (Figure 2). In contrast to the initial
experience with analysis of the UK NEQAS test sample, the QC
rounds showed a high level of concordance between the results
obtained by the respective testing laboratories despite the use of
different qPCR platforms, with plots of Ct values for each of the
dilutions lying largely in parallel (Figure 3). Moreover, Assays 2,
5 and 7 were conﬁrmed to provide reliable quantiﬁcation between
laboratories within the diagnostic range, as shown by close
correlation with the percentage of JAK2-V617F, as determined
by pyrosequencing (Supplementary Figure 2), indicating their
suitability for use in the routine diagnostic setting.
Following a further QC round, Cyclophilin was dropped,
as reproducibility was found to be poorer as compared with the
ALB assay, which is widely used as a control gene in the MRD
detection of acute lymphoblastic leukemia. With the aim of
selecting the best assays for the tracking of MRD (%JAK2-V617Fo1),
in QC5, two further ‘in-house’ assays were evaluated (Assays
8 and 9), but were eliminated because they exhibited poorer
speciﬁcity when tested on serial dilutions of HEL in K562 cells. On
the basis of two more QC rounds, Assays 2 and 6 were also
eliminated; the former generally afforded poorer speciﬁcity,
whereas the latter was less efﬁcient (slope—4.21, y intercept
51.5), rendering them less suitable for MRD monitoring (Figure 2)
as compared with Assays 5 and 7 (slopes—3.5, y intercept 41,
Figure 2) for which the majority of laboratories detected the 0.08%
dilution (Table 1).
Evaluation of speciﬁcity of JAK2-V617F assays in control
PB samples
Although the two best-performing JAK2-V617F assays showed
limited cross-reactivity with the wild-type allele on analysis of
undiluted K562 cells, with most laboratories reporting Ct values
440 (see plots for 0% JAK2-V617F for Assays 5 and 7, Figure 3), we
subsequently formally evaluated assay speciﬁcity in a large
number of PB samples (n¼ 100) derived from individuals with
no history of MPN. For these experiments, ALB was used to
provide an independent reference to control for the amount of
DNA template, with the level of background ampliﬁcation with
the JAK2-V617F assay assessed by the DCt method. Some
cross-reactivity was observed with Assay 7, with Ct values
of o40 observed in the majority (54%), with median Ct 39.9
(range 38.6–50). Assay 5 exhibited less cross-reactivity, with Ct
values o40 cycles observed in only 3% of samples (median 40.9,
range 39.9–50.0) (Supplementary Figure 3). Accordingly, there was
a greater difference in DCtJAK2-V617F-ALB for Assay 5 (median 14.1,
range 13.3–21.6) as compared with Assay 7 (median 13.2, range
11.7–21.6), suggesting that Assay 5 may have a marginally better
speciﬁcity and performance proﬁle for MRD assessment, more
reliably distinguishing low level residual disease from non-speciﬁc
background.
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Figure 3. Interlaboratory concordance of JAK2-V617F quantification. Left panel: shows the design of Assays 2, 5 and 7, which were found to
afford the greatest sensitivity for the detection of JAK2-V617F. Right panel: graphs show mean Ct value for the respective JAK2-V617F assays
reported by each laboratory obtained on the analysis of DNA from serial dilutions of HEL in K562 cells in the third QC round (QC3). Plots of the
dilution series were observed to lie largely in parallel, with all laboratories successfully detecting the 0.5% JAK2-V617F dilution (with Ct values
o40 cycles recorded by all laboratories with each assay). The Ct values observed with neat K562 cells (labeled as 0% JAK2-V617F) generally
exceeded 40 cycles (with the exception of laboratory 2 and laboratory 4 for Assay 2 and Assay 7, respectively), consistent with specificity of the
JAK2-V617F assays for the mutant allele with the test conditions applied in the majority of the laboratories.
0
5
10
15
20
25
30
35
40
0.0 1.0 2.0 3.0 4.0 5.0
V617F
0
5
10
15
20
25
30
35
40
0.0 1.0 2.0 3.0 4.0 5.0
Standards Assay 7
V617F
0
5
10
15
20
25
30
35
40
45
50
0.0 1.0 2.0 3.0 4.0 5.0
Standards Assay 6
V617F
0
5
10
15
20
25
30
35
40
0.0 1.0 2.0 3.0 4.0 5.0
Standards Assay 5
V617F
0
5
10
15
20
25
30
35
40
0.0 1.0 2.0 3.0 4.0 5.0
Standards Cyclophilin
Cyclophilin
0
5
10
15
20
25
30
35
40
0.0 1.0 2.0 3.0 4.0 5.0
Standards Albumin
Albumin
y = -4.21x + 51.543
R² = 0.9985
y = -3.516x + 40.608
R² = 0.9977
y = -3.5025x + 41.088
R² = 0.9996
y = -3.5965x + 43.429
R² = 0.9988
y = -3.5915x + 40.968
R² = 1
y = -3.5995x + 40.563
R² = 0.9998
Standards Assay 2
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serial dilutions of plasmid standards. The efficiencies of JAK2-V617F Assays 2, 5 and 7 were found to be superior to that of Assay 6, with slope values
much closer to  3.32 (the slope associated with a PCR reaction with maximal efficiency). y-axis: Mean cycle threshold (Ct) values; x-axis: log dilution.
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The two best-performing JAK2-V617F assays for MRD tracking
predict outcome following allogeneic transplant
To assess the reliability of the most sensitive assays (Assays 5 and 7)
to detect MRD and to predict outcome, they were evaluated in
stored samples from a cohort of 28 patients with a range of JAK2-
V617F-positive myeloid neoplasms (including PMF, PV, trans-
formed MPN and chronic myelomonocytic leukemia) who underwent
allogeneic stem cell transplantation, mostly with reduced intensity
conditioning given the age of the patients concerned
(median 54 years). Overall, comparison of the results obtained
with the two assays in pre- and post-transplant samples showed
very close concordance—r¼ 0.98, Po0.0001 (Supplementary
Figure 4). All cases tested positive for JAK2-V617F immediately
before transplant, with 17 patients achieving molecular remission
at a median of 108 days (range 23–1488 days). Five patients
remained in molecular remission at date of last follow-up
(3–25 months post-transplant), testing negative for JAK2-V617F
without any ﬂuctuation or background ampliﬁcation. In 12
patients after initial molecular remission, the qPCR assays detected
recurrence of JAK2-V617F positivity; this predicted clinical relapse
in 9 patients 1.5–19.6 months later, predating the loss of full donor
chimerism by 1.5–12.2 months (Figure 4). Three patients with PCR
positivity were still reported to be in clinical remission at the time
of last follow-up (3–8 months later). Clinical relapses were
predicted by prior JAK2-V617F positivity by the qPCR assays, with
the exception of one case, where there was a prolonged interval
(10 months) between relapse and the preceding MRD assessment.
The kinetics of relapse was highly variable, with the JAK2-V617F
mutant allele rising by a median of 0.6 logs/month (range 0.1–1.3
logs/month). In seven patients, donor lymphocyte infusion (DLI)
was administered for clinical relapse (myeloﬁbrosis, n¼ 4,
transformed MPN, n¼ 3) leading to disease response in four
patients (three myeloﬁbrosis, one transformed MPN), associated
with the achievement of molecular remission by qPCR (Figure 4).
DISCUSSION
The advent of high throughput sequencing technologies has led
to major advances in deﬁning the mutational landscape of
hematological malignancies. This information has not only helped
reﬁne disease diagnosis and discern potential therapeutic targets,
but also provides opportunities to develop assays to detect MRD,
tracking response to therapy. Extensive standardization efforts
have been undertaken to establish optimal qPCR assays to detect
leukemia-speciﬁc targets, for example, BCR-ABL1 and other fusion
gene transcripts arising from balanced chromosomal rearrange-
ments, as well as immunoglobulin and T-cell receptor gene
rearrangements in lymphoid malignancies.46,48 These initiatives
have been highly inﬂuential, leading to the implementation of
standardized assays, which have been shown to provide
independent prognostic information, to guide therapy within
clinical trials. However, a number of hematological malignancies
are characterized by point mutations, for example, BRAF-V600E in
hairy cell leukemia and JAK2-V617F in MPNs, which can also
potentially be detected and tracked by sensitive qPCR assays to
predict treatment outcome.26–29,49 Point mutations present more
challenging MRD targets as compared with leukemic fusion
genes due to potential problems relating to cross-reactivity of
the mutant assay with the wild-type allele (reviewed12), with
a previous study showing that the most sensitive and accurate
approach for detection of JAK2-V617F involves qPCR with
mutation-speciﬁc primers.10
For patients with suspected MPNs, there is a critical need
for robust and sensitive assays to detect JAK2-V617F, with
mutant allele burden reported to correlate with biologically and
prognostically distinct subsets of disease (reviewed6). Importantly,
it has become clear that the level of JAK2-V617F detectable in the
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PB of some patients with bona ﬁde MPNs can be as low as 1% at
the time of diagnosis,6–10 which is below the detection limit of
some standard diagnostic methods, such as pyrosequencing.10,11
Since the discovery of the JAK2-V617F mutation, numerous qPCR
assays have been designed to detect this abnormality,10,12,50
which we have shown vary markedly in their sensitivity and
speciﬁcity. Previous studies have highlighted the potential of qPCR
assessment of JAK2-V617F allele burden to predict outcome
following allogeneic transplant in PMF,26–29 with reduction of
JAK2-V617F to o1% by 1 month30 or achievement of PCR
negativity in the PB by 6 months post-transplant, distinguishing
patients at markedly differing risk of subsequent disease relapse.29
However, these time points were not particularly informative in
the present study, which may reﬂect the greater heterogeneity of
the patients analyzed.
Previous reports have highlighted the importance of serial MRD
assessment post-transplant as a potential tool to guide immuno-
suppression and administration of DLI.29–32 We observed that DLI
given at time of clinical relapse induced molecular remission as
determined by qPCR in four patients (Figure 4), lending further
support for a graft vs MPN effect. Chimerism analysis currently
provides the mainstay for post-transplant surveillance, with loss of
donor chimerism used to direct DLI and reduce the risk of disease
relapse. However, chimerism assays do not directly assess the
presence of MRD and are relatively insensitive. Indeed, in the
present study we found that qPCR assays detected JAK2-V617F
positivity long before loss of full donor chimerism and clinical
relapse. In accordance with the experience in chronic myeloid
leukemia, where DLI has been shown to be more effective in the
context of MRD as compared with cytogenetic or hematological
relapse (reviewed51), there is evidence to suggest that early
intervention with DLI in the context of molecular relapse of
JAK2-V617F-associated PMF post-transplant is associated with a
better response rate compared with salvage at time of overt
relapse.31 Therefore, there is now a strong rationale for the
adoption of regular qPCR assessment for JAK2-V617F following
allogeneic transplant in informative patients to complement
chimerism analysis.52
Although results obtained with Assays 5 and 7 in pre- and post-
transplant patient samples were found to be highly concordant
(Supplementary Figure 4), the assessment of control PB samples
suggested that Assay 5, previously published by Larsen et al.43
may more reliably distinguish low level MRD from background
ampliﬁcation. Indeed, this assay has been applied in the
diagnostic setting in a large population-based study to
discriminate JAK2-V617F status,53 following a Chinese study that
reported the detection of low level JAK2-V617F positivity in
individuals with no clinical evidence of an MPN.54 Here, we
signiﬁcantly extend this study, showing that the selected
ELN/MPN&MPNr-EuroNet JAK2-V617F assay (Assay 5) can be
used to reliably track MRD, suitable for guiding management
post-transplant. Importantly, we found that this assay performed
well across different qPCR platforms (Table 1), giving rise to
comparable results, and therefore can be recommended for
assessing the impact of novel therapies on the malignant clone in
clinical trials, as well being implemented into the routine
management of patients undergoing allogeneic transplantation.
The recommended qPCR assay should provide a benchmark
against which to assess sensitivity and speciﬁcity of high-
throughput sequencing approaches to detect point mutations
such as JAK2-V617F, which promise to extend the molecular
detection of MRD to much greater proportions of patients with
hematological malignancies, thereby allowing development of
more personalized treatment approaches.
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Figure 4. Investigation of best-performing JAK2-V617F qPCR assays to predict outcome following allogeneic transplantation. Stored PB
samples from patients with JAK2-V617F-positive myeloid disorders were tested in parallel using JAK2-V617F Assays 5 and 7, in conjunction
with ALB as an independent control gene. Samples were determined to be positive or negative for JAK2-V617F according to the DCt between
the JAK2-V617F and ALB amplification plots, taking into account the cut offs defined in control PB samples for each mutant assay (see
Supplementary Figure 3), with PCR-positive and -negative samples denoted by filled and empty data points, respectively. JAK2-V617F
percentage for PCR-positive samples was calculated using the matching wild-type and total JAK2 assays for the respective assays. PCR profiles
are shown from four (UPN1–4) of the 28 patients evaluated, who underwent allogeneic transplant with reduced intensity conditioning with an
unrelated (UPN1) or sibling donor (UPN2–4) for PMF (UPN2, UPN3) or JAK2-V617F-positive secondary acute myeloid leukemia arising on
a background of MPN (UPN1, UPN4). In each case, the clinical relapse post-transplant was predicted by JAK2-V617F positivity with a rise in
mutant level (UPN1, UPN3 and UPN4) or persistently high levels (UPN2). JAK2-V617F detection by qPCR preceded loss of donor chimerism
in UPN1, UPN3 and UPN4. Three patients received DLI, denoted by blue arrows, inducing molecular remission. Chimerism was assessed by
microsatellite marker analysis in UPN1, UPN3 and UPN4 and by fluorescence in situ hybridization analysis of X and Y chromosomes in UPN2.
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